Endocrinology Search
Endocrinology Endocrinology
diabetes%20mellitus
DIABETES MELLITUS
Diabetes mellitus (DM) is a heterogenous metabolic disorder characterized by the presence of hyperglycemia with carbohydrate, protein and fat metabolism disturbance which results from defects in either insulin secretion or action.
Patients with DM usually present with polyuria, polydipsia and unexplained weight loss.
Type 1 DM is caused by beta cell destruction which leads to complete insulin deficiency. It may be immune mediated or idiopathic.
Patients may present with ketoacidosis or acute onset of hyperglycemia while other patients may resemble type 2 DM or symptoms of other autoimmune disorders.
Type 2 DM is the most common form of diabetes. It is secondary to defect in insulin secretion concomitant with insulin resistance.
Majority of patients are asymptomatic. Ketoacidosis is uncommon and is usually secondary to stress (eg infection).
Drug Information

Indication: NIDDM (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to co...

Indication: Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy; a...

Indication: Type 2 DM in adult particularly in overwt patients when dietary management & exercise alone does not resul...

Glyxambi
empagliflozin + linagliptin

Indication: Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM when treatment w/ both empag...

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Type 2 DM as monotherapy in patients inadequately controlled by diet & exercise alone & for whom metfo...

Indication: Adjunct to diet & exercise to improve glycaemic control in adult patients w/ type 2 DM when treatment w/ b...

Lusefi
luseogliflozin hydrate

Indication: Monotherapy or add-on combination therapy w/ sulfonylurea in adult patients w/ type 2 DM.

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Qtern
dapagliflozin + saxagliptin

Indication: Type 2 DM inadequately controlled on metformin alone or when already treated w/ fixed-dose combination in adul...

1  /  17
1  /  17
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Newly approved oral anti-diabetic medication now available in Malaysia
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
DIABESITY AND THE ROLE OF DIABETIC-SPECIFIC FORMULA IN IMPROVING DIABETES AND OBESITY OUTCOMES
02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin slows eGFR decline in diabetics
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
Diabetes mellitus negatively influences pancreatic cancer outcomes
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.